Farmers Trust Co. decreased its stake in shares of Amgen, Inc. (NASDAQ:AMGN) by 18.7% in the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 23,555 shares of the medical research company’s stock after selling 5,427 shares during the period. Amgen makes up about 1.2% of Farmers Trust Co.’s investment portfolio, making the stock its 28th largest holding. Farmers Trust Co.’s holdings in Amgen were worth $4,097,000 as of its most recent filing with the Securities & Exchange Commission.
Several other hedge funds also recently modified their holdings of the company. Baker Ellis Asset Management LLC bought a new position in Amgen in the third quarter valued at $108,000. Phocas Financial Corp. bought a new position in Amgen in the second quarter valued at $110,000. Jackson Grant Investment Advisers Inc. grew its position in Amgen by 0.8% in the second quarter. Jackson Grant Investment Advisers Inc. now owns 641 shares of the medical research company’s stock valued at $110,000 after purchasing an additional 5 shares in the last quarter. Omnia Family Wealth LLC grew its position in Amgen by 25.3% in the second quarter. Omnia Family Wealth LLC now owns 729 shares of the medical research company’s stock valued at $125,000 after purchasing an additional 147 shares in the last quarter. Finally, Horan Capital Advisors LLC. bought a new position in Amgen in the third quarter valued at $150,000. 78.61% of the stock is owned by institutional investors.
In other news, EVP Sean E. Harper sold 1,525 shares of the firm’s stock in a transaction dated Wednesday, February 14th. The shares were sold at an average price of $174.18, for a total transaction of $265,624.50. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. In the last 90 days, insiders have sold 4,575 shares of company stock valued at $818,361. 0.19% of the stock is currently owned by corporate insiders.
Shares of Amgen, Inc. (NASDAQ:AMGN) opened at $190.35 on Wednesday. The company has a debt-to-equity ratio of 1.35, a quick ratio of 5.17 and a current ratio of 5.49. The stock has a market cap of $137,000.50, a PE ratio of 74.07, a PEG ratio of 2.27 and a beta of 1.37. Amgen, Inc. has a 12 month low of $152.16 and a 12 month high of $201.23.
Amgen (NASDAQ:AMGN) last posted its earnings results on Thursday, February 1st. The medical research company reported $2.89 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $3.03 by ($0.14). The company had revenue of $5.80 billion for the quarter, compared to analyst estimates of $5.84 billion. Amgen had a return on equity of 30.87% and a net margin of 8.66%. The business’s quarterly revenue was down 2.7% compared to the same quarter last year. During the same quarter in the prior year, the business posted $2.89 EPS. research analysts forecast that Amgen, Inc. will post 13.21 earnings per share for the current year.
Amgen announced that its Board of Directors has authorized a stock repurchase program on Thursday, February 1st that allows the company to repurchase $10.00 billion in shares. This repurchase authorization allows the medical research company to buy shares of its stock through open market purchases. Stock repurchase programs are often a sign that the company’s leadership believes its shares are undervalued.
The business also recently announced a quarterly dividend, which will be paid on Thursday, March 8th. Stockholders of record on Thursday, February 15th will be paid a dividend of $1.32 per share. This represents a $5.28 dividend on an annualized basis and a dividend yield of 2.77%. The ex-dividend date of this dividend is Wednesday, February 14th. This is a boost from Amgen’s previous quarterly dividend of $1.15. Amgen’s dividend payout ratio (DPR) is currently 205.45%.
AMGN has been the subject of a number of analyst reports. Oppenheimer reaffirmed a “buy” rating and issued a $205.00 target price on shares of Amgen in a research report on Thursday, November 30th. Cann reaffirmed a “buy” rating and issued a $205.00 target price on shares of Amgen in a research report on Thursday, November 30th. Goldman Sachs Group downgraded shares of Amgen from a “conviction-buy” rating to a “buy” rating in a research report on Friday, December 15th. Piper Jaffray Companies reaffirmed a “buy” rating on shares of Amgen in a research report on Tuesday, January 2nd. Finally, Mizuho set a $192.00 target price on shares of Amgen and gave the company a “buy” rating in a research report on Thursday, December 28th. One investment analyst has rated the stock with a sell rating, fifteen have issued a hold rating and eleven have assigned a buy rating to the stock. The stock presently has an average rating of “Hold” and an average target price of $191.72.
Amgen Inc is a biotechnology company. The Company discovers, develops, manufactures and delivers various human therapeutics. It operates in human therapeutics segment. Its marketed products portfolio includes Neulasta (pegfilgrastim); erythropoiesis-stimulating agents (ESAs), such as Aranesp (darbepoetin alfa) and EPOGEN (epoetin alfa); Sensipar/Mimpara (cinacalcet); XGEVA (denosumab); Prolia (denosumab); NEUPOGEN (filgrastim), and other marketed products, such as KYPROLIS (carfilzomib), Vectibix (panitumumab), Nplate (romiplostim), Repatha (evolocumab), BLINCYTO (blinatumomab), IMLYGIC (talimogene laherparepvec) and Corlanor (ivabradine).
Want to see what other hedge funds are holding AMGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Amgen, Inc. (NASDAQ:AMGN).